Draft Agenda:

 

Early Toxicity Screening 2008 (ETS 2008): 

Metabolism-Based Drug Toxicity in Drug Development

 

Date:  June 5 - 6, 2008

 

Venue:  Red Lion Inn, Seattle, Washington, USA

 

Preliminary Agenda

 

  1. Keynote Presentation:  Role of drug metabolism in drug-induced liver toxicity. Sid Nelson, University of Washington
  2. Evaluation of metabolism-based drug toxicity:  Pharma perspectives
    1. Reactive metabolites and marketed Drugs:  What is the evidence and what are the consequences?  John C. L. Erve, Wyeth Research
    2. Target-based toxicity screening in drug development – global and focused tools. Stefan Otto Mueller, Merck AG
    3. Toxicity screening in drug discovery and early drug development. Robert Dunn, Amgen Inc.

 

  1. In vitro tools for the evaluation of metabolism-based drug toxicity
    1. Human hepatocyte assays for metabolism-based toxicity. Albert Li, APSciences and IVAL
    2. Tissue slices for the evaluation of metabolism-based toxicity. Alison Vickers, Allergan
    3. Hepatocyte assay for the screening of canalicular transporter inhibitors.   Gerry Kenna, Astrazeneca
    4. Human hepatocyte assay for canaliculi inhibitors.   Jim Xu, Pfizer Research Technology Center

 

  1. Identification and Quantification of Cytotoxic/Reactive Metabolites
    1. Identification of reactive metabolites by mass spectrometry. Shuguang Ma (Invited)
    2. High throughput screening analysis of reactive metabolites Zhengyin Yan; Johnson & Johnson PRD
    3. Metabolites in safety testing.   Dennis Smith; Pfizer Global R&D
    4. Safety testing of metabolites:  Is it necessary? Sandy Pang; University of Toronto
    5. Reactive metabolite target protein database.  Robert Hanzlik, University of Kansas